Matthew Sykes
Stock Analyst at Goldman Sachs
(4.01)
# 565
Out of 5,090 analysts
210
Total ratings
52.41%
Success rate
10.68%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $5 | $14.24 | -64.89% | 4 | May 14, 2025 | |
| CTKB Cytek Biosciences | Maintains: Sell | $3.5 → $3 | $4.99 | -39.88% | 14 | May 12, 2025 | |
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $17.77 | -63.42% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $48.03 | -6.31% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $7.09 | +12.83% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $32.30 | +48.61% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $16.75 | +1.49% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $185.80 | -13.89% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $11.90 | -15.97% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $100.79 | +24.02% | 2 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $10.93 | +28.09% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $240 | $226.25 | +6.08% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $18.53 | +40.31% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $184.31 | -7.76% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $102.02 | -45.11% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $158.96 | -49.67% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $2.39 | -37.24% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $244.55 | -22.31% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $2.03 | -13.58% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $3.70 | +14.86% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $44.61 | -17.06% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $101.06 | -35.68% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $225.85 | +10.69% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $7.63 | +214.55% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,414.86 | -8.12% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $9.25 | +29.73% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $572.77 | +11.74% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $145.49 | -0.34% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $47.01 | - | 5 | Dec 7, 2023 |
Fortrea Holdings
May 14, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $14.24
Upside: -64.89%
Cytek Biosciences
May 12, 2025
Maintains: Sell
Price Target: $3.5 → $3
Current: $4.99
Upside: -39.88%
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $17.77
Upside: -63.42%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $48.03
Upside: -6.31%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $7.09
Upside: +12.83%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $32.30
Upside: +48.61%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $16.75
Upside: +1.49%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $185.80
Upside: -13.89%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $11.90
Upside: -15.97%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $100.79
Upside: +24.02%
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $10.93
Upside: +28.09%
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $226.25
Upside: +6.08%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $18.53
Upside: +40.31%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $184.31
Upside: -7.76%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $102.02
Upside: -45.11%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $158.96
Upside: -49.67%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $2.39
Upside: -37.24%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $244.55
Upside: -22.31%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $2.03
Upside: -13.58%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $3.70
Upside: +14.86%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $44.61
Upside: -17.06%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $101.06
Upside: -35.68%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $225.85
Upside: +10.69%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $7.63
Upside: +214.55%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,414.86
Upside: -8.12%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $9.25
Upside: +29.73%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $572.77
Upside: +11.74%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $145.49
Upside: -0.34%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $47.01
Upside: -